BACKGROUND: Policy-makers have called for efforts to reduce overuse of cancer screening tests, including colorectal cancer screening (CRCS). Overuse of CRCS tests other than colonoscopy has not been well documented. OBJECTIVE: To estimate levels and correlates of fecal occult blood test (FOBT) overuse in a national Veterans Health Administration (VHA) sample. DESIGN: Observational PARTICIPANTS: Participants included 1,844 CRCS-eligible patients who responded to a 2007 CRCS survey conducted in 24 VHA facilities and had one or more FOBTs between 2003 and 2009. MAIN MEASURES: We combined survey data on race, education, and income with administrative data on region, age, gender, CRCS procedures, and outpatient visits to estimate overuse levels and variation. We coded FOBTs as overused if they were conducted <10 months after prior FOBT, <9.5 years after prior colonoscopy, or <4.5 years after prior barium enema. We used multinomial logistic regression models to examine variation in overuse by reason (sooner than recommended after prior FOBT; sooner than recommended after colonoscopy, barium enema, or a combination of procedures), adjusting for clustering of procedures within patients, and patients within facilities. KEY RESULTS: Of 4,236 FOBTs received by participants, 885 (21 %) met overuse criteria, with 323 (8 %) sooner than recommended after FOBT, and 562 (13 %) sooner than recommended after other procedures. FOBT overuse varied across facilities (9-32 %, p<0.0001) and region (12-23 %, p< .0012). FOBT overuse after prior FOBT declined between 2003 and 2009 (8 %-5 %, p= .0492), but overuse after other procedures increased (11-19 %, p= .0002). FOBT overuse of both types increased with number of outpatient visits (OR 1.15, p<0.001), but did not vary by patient demographics. More than 11 % of overused FOBTs were followed by colonoscopy within 12 months. CONCLUSIONS: Many FOBTs are performed sooner than recommended in the VHA. Variation in overuse by facility, region, and outpatient visits suggests addressing FOBT overuse will require system-level solutions.
BACKGROUND: Policy-makers have called for efforts to reduce overuse of cancer screening tests, including colorectal cancer screening (CRCS). Overuse of CRCS tests other than colonoscopy has not been well documented. OBJECTIVE: To estimate levels and correlates of fecal occult blood test (FOBT) overuse in a national Veterans Health Administration (VHA) sample. DESIGN: Observational PARTICIPANTS: Participants included 1,844 CRCS-eligible patients who responded to a 2007 CRCS survey conducted in 24 VHA facilities and had one or more FOBTs between 2003 and 2009. MAIN MEASURES: We combined survey data on race, education, and income with administrative data on region, age, gender, CRCS procedures, and outpatient visits to estimate overuse levels and variation. We coded FOBTs as overused if they were conducted <10 months after prior FOBT, <9.5 years after prior colonoscopy, or <4.5 years after prior barium enema. We used multinomial logistic regression models to examine variation in overuse by reason (sooner than recommended after prior FOBT; sooner than recommended after colonoscopy, barium enema, or a combination of procedures), adjusting for clustering of procedures within patients, and patients within facilities. KEY RESULTS: Of 4,236 FOBTs received by participants, 885 (21 %) met overuse criteria, with 323 (8 %) sooner than recommended after FOBT, and 562 (13 %) sooner than recommended after other procedures. FOBT overuse varied across facilities (9-32 %, p<0.0001) and region (12-23 %, p< .0012). FOBT overuse after prior FOBT declined between 2003 and 2009 (8 %-5 %, p= .0492), but overuse after other procedures increased (11-19 %, p= .0002). FOBT overuse of both types increased with number of outpatient visits (OR 1.15, p<0.001), but did not vary by patient demographics. More than 11 % of overused FOBTs were followed by colonoscopy within 12 months. CONCLUSIONS: Many FOBTs are performed sooner than recommended in the VHA. Variation in overuse by facility, region, and outpatient visits suggests addressing FOBT overuse will require system-level solutions.
Authors: Theodore R Levin; Wei Zhao; Carol Conell; Laura C Seeff; Diane L Manninen; Jean A Shapiro; Jane Schulman Journal: Ann Intern Med Date: 2006-12-19 Impact factor: 25.391
Authors: Melissa R Partin; Joseph Grill; Siamak Noorbaloochi; Adam A Powell; Diana J Burgess; Sally W Vernon; Krysten Halek; Joan M Griffin; Michelle van Ryn; Deborah A Fisher Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04-01 Impact factor: 4.254
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Kimberly S Andrews; Durado Brooks; John Bond; Chiranjeev Dash; Francis M Giardiello; Seth Glick; David Johnson; C Daniel Johnson; Theodore R Levin; Perry J Pickhardt; Douglas K Rex; Robert A Smith; Alan Thorson; Sidney J Winawer Journal: Gastroenterology Date: 2008-02-08 Impact factor: 22.682
Authors: Alex H Krist; Resa M Jones; Steven H Woolf; Sarah E Woessner; Daniel Merenstein; J William Kerns; Walter Foliaco; Paul Jackson Journal: Am J Prev Med Date: 2007-12 Impact factor: 5.043
Authors: Victoria S Benson; Julietta Patnick; Anna K Davies; Marion R Nadel; Robert A Smith; Wendy S Atkin Journal: Int J Cancer Date: 2008-03-15 Impact factor: 7.396
Authors: Mary E Charlson; Robert E Charlson; Janey C Peterson; Spyridon S Marinopoulos; William M Briggs; James P Hollenberg Journal: J Clin Epidemiol Date: 2008-07-10 Impact factor: 6.437
Authors: Zachary Predmore; Jean Pannikottu; Ritu Sharma; Monica Tung; Stephanie Nothelle; Jodi B Segal Journal: Am J Med Qual Date: 2018-03-16 Impact factor: 1.852
Authors: Adam A Powell; Sameer D Saini; Matthew K Breitenstein; Siamak Noorbaloochi; Andrea Cutting; Deborah A Fisher; Hanna E Bloomfield; Krysten Halek; Melissa R Partin Journal: J Gen Intern Med Date: 2015-01-21 Impact factor: 5.128
Authors: Caitlin C Murphy; Robert S Sandler; Janet M Grubber; Marcus R Johnson; Deborah A Fisher Journal: Clin Gastroenterol Hepatol Date: 2015-10-19 Impact factor: 11.382